Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: January 10, 2024
Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations.
Journal: JTO clinical and research reports
Published: June 02, 2023
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
Journal: Expert review of anticancer therapy
Published: December 20, 2022
Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 24, 2022
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
Journal: Journal of clinical medicine
Published: November 21, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.
Journal: Clinical pharmacology and therapeutics
Published: December 23, 2021
Showing 1-7 of 7
Last Updated: 09/26/2026